Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy

Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027
Authors:
Shayan Dioun
Ling Chen
Alexandre Buckley De Meritens
Caryn M St Clair
June Y Hou
Fady Khoury-Collado
Tarah Pua
Dawn L Hershman
Jason D Wright
Affiliated Authors:
Shayan Dioun
Ling Chen
Alexandre Buckley De Meritens
Caryn M St Clair
June Y Hou
Fady Khoury-Collado
Tarah Pua
Dawn L Hershman
Jason D Wright
Columbia Affiliation:
Subjects:
DNA Mismatch Repair (MeSH)
Endometrial Neoplasms (MeSH)
Phenylurea Compounds (MeSH)
Quinolines (MeSH)
Antibodies, Monoclonal, Humanized (MeSH)
Author Keywords:
lenvatinib
pembrolizumab
endometrial cancer
uterine cancer
immunotherapy
elink
Publication Type:
Article
Unique ID:
10.1016/j.ygyno.2023.12.027
PMID:
38262241
DOI:
10.1016/j.ygyno.2023.12.027
Journal:
Gynecologic Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: